<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00536835</url>
  </required_header>
  <id_info>
    <org_study_id>PLK107427</org_study_id>
    <nct_id>NCT00536835</nct_id>
  </id_info>
  <brief_title>Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma</brief_title>
  <official_title>A Phase I Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of [GSK461364], a Polo-like Kinase 1 (PLK1) Inhibitor, in Adult Subjects With Advanced Solid Tumor or Non-Hodgkins Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This is a first time in human study that is being done to determine the maximum tolerated
      dose and initial pharmacokinetic parameters of GSK461364, given by IV, in adult subjects with
      solid tumors and Non-Hodgkins lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 16, 2007</start_date>
  <completion_date type="Actual">September 29, 2009</completion_date>
  <primary_completion_date type="Actual">September 29, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma levels for GSK461364 will be taken at:Schedule 1:Day 1, 8, 15, &amp; 22 for Cycle 1 and Day 1, 8 &amp; 15 for subsequent cycles.Schedule 2:Day 1, 2, 8, 9, 15, &amp; 16 for all cycles.Schedule 3:Day 1 to 5 for all cycles.</measure>
    <time_frame>16 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated by: - Physical exam at screen &amp; then D1 for each cycle - 12 lead ECG &amp; telemetry at screen &amp; Wk 1 to 3 for Schedule 1 &amp; 2, &amp; Wk 1 &amp; 2 (ECG only) for Schedule 3. - Lab tests &amp; AE monitoring throughout the study.</measure>
    <time_frame>16 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Stage A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage A will identify maximum tolerated doses for either Schedule 1 - GSK461364 given once weekly on Day 1, 8 and 15 every 28 days; Schedule 2 - GSK 461364 given twice weekly Days 1, 2, 8, 9, 15 and 16; Schedule 3 Daily on Day 1 to Day 15 every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluate safety, PK, pharmacodynamic (PD) &amp; tumor response in expanded cohorts at the MTD for at least one schedule from Stage A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK461364</intervention_name>
    <description>GSK461364 will be given intravenously as a 4 hour infusion in either a final volume of 500 or 1000 mLs. The starting dose for Stage A - Schedule 1 was 50 mg and doses were to be escalated as described in protocol until maximum tolerated dose established.</description>
    <arm_group_label>Stage B</arm_group_label>
    <arm_group_label>Stage A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of advanced solid tumor or Non-Hodgkins Lymphoma (excluding
             HIV-associated lymphoma) that has relapsed or is refractory to standard therapies

          -  At least 18 years of age

          -  Female who are of non-childbearing potential or who have a negative pregnancy test who
             uses approved contraception

          -  Male with a female partner of childbearing potential must have had a vasectomy or both
             are using approved contraception

          -  Lab values that are within range as described in the protocol

          -  Paraffin-embedded archival tumor tissue available for testing

          -  Signed written informed consent

        Exclusion Criteria:

          -  Undergone major surgery or received anti-cancer therapy

          -  History of hemolytic anemia

          -  Clinical lab tests that are out of range as described in the protocol

          -  Females who are pregnant or lactating

          -  Significant heart problems

          -  Serious or unstable pre-existing medical or psychiatric condition

          -  Are not able to comply with the study protocol

          -  Use of prohibited medications

          -  Have low blood pressure

          -  Evidence of symptomatic or untreated central nervous system involvement and require
             corticosteroids or anti-epileptic meds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Belfast, Northern Ireland</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/PLK107427?search=study&amp;study_ids=107427#rs</url>
    <description>Results for study 107427 can be found on the GSK Clinical Study Register.</description>
  </link>
  <reference>
    <citation>Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, Barriuso J, Medani H, Degenhardt YY, Allred AJ, Smith DA, Murray SC, Lampkin TA, Dar MM, Wilson R, de Bono JS, Blagden SP. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res. 2011 May 15;17(10):3420-30. doi: 10.1158/1078-0432.CCR-10-2946. Epub 2011 Apr 1.</citation>
    <PMID>21459796</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2007</study_first_submitted>
  <study_first_submitted_qc>September 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2007</study_first_posted>
  <last_update_submitted>June 23, 2017</last_update_submitted>
  <last_update_submitted_qc>June 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Hodgkins Lymphoma</keyword>
  <keyword>Cancer</keyword>
  <keyword>First time in human</keyword>
  <keyword>PLK1 inhibitor</keyword>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>GSK461364</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>PLK107427</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PLK107427</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PLK107427</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PLK107427</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PLK107427</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PLK107427</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>PLK107427</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

